Bevacizumab has shown some efficacy in spinal cord ependymomas occurring in NF2 patients, especially when these tumors harbor an important cystic component [78], and can also result in some response in recurrent spinal cord ependymomas [75]. The gene discussed is NF2; the disease is spinal cord ependymoma.